PTH Blood Test Explained: What It Measures and Why It's Ordered

Parathyroid hormone (PTH) is one of the most frequently measured peptide hormones in clinical chemistry, and the test that quantifies it sits at the centre of how calcium disorders are classified. This page summarises what the analyte is, how laboratories measure it, the reasons the published literature gives for ordering it, and the analytical caveats that reviews have repeatedly flagged. This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory result, symptom or treatment decision. No reference ranges, thresholds or interpretations of an individual result appear here, because those belong to the clinician who ordered the test and the laboratory that ran it.

What PTH Is and Where It Comes From

PTH is an 84-amino-acid peptide secreted by the four parathyroid glands, which sit adjacent to the thyroid. Its release is governed largely by the calcium-sensing receptor on parathyroid cells, so secretion rises when extracellular ionised calcium falls and is suppressed when calcium rises. A review of calcium and bone metabolism indices described PTH as one of a linked panel of analytes — calcium, phosphate, magnesium, vitamin D metabolites and bone turnover markers — that are interpreted together rather than in isolation (PMID 28939209).

Once released, PTH acts on bone and kidney: it mobilises calcium from the skeleton, increases renal calcium reabsorption, promotes phosphate excretion, and stimulates conversion of 25-hydroxyvitamin D to its active 1,25-dihydroxy form, which in turn increases intestinal calcium absorption. The same review framed these indices as the backbone of mineral metabolism assessment in clinical laboratories (PMID 28939209).

Intact PTH has a short circulating half-life, and the hormone is cleaved into fragments in the liver, kidney and at the gland itself. Those fragments are the reason the "PTH test" is not a single, uniform measurement — a point addressed in detail in the assay sections below.

What the Test Actually Measures

PTH is measured in serum or EDTA plasma by two-site immunoassays, typically automated chemiluminescent platforms. A review of the problems with PTH assays described how successive assay generations capture different mixtures of circulating peptides: early radioimmunoassays detected mid-region and C-terminal fragments, second-generation "intact" assays also cross-react with large N-terminally truncated fragments such as PTH(7-84), and third-generation "whole" or "bio-intact" assays were designed to recognise only the full-length 1-84 molecule (PMID 25916762). Researchers in that review emphasised that results from different manufacturers are not interchangeable because of this fragment cross-reactivity and the absence of a universal standard (PMID 25916762).

A kidney-focused review of PTH measurement in chronic kidney disease (CKD) made the same point in a different setting, reporting substantial between-method differences in PTH values from identical samples and discussing how that variability complicates the use of fixed numerical targets in guidelines (PMID 19812537).

Why Clinicians Order a PTH Test, as Described in the Literature

Sorting out high calcium

The dominant published use is pairing PTH with a calcium measurement. A clinical review of hypercalcaemia described the first diagnostic step as separating PTH-dependent hypercalcaemia, in which PTH is elevated or inappropriately non-suppressed, from PTH-independent hypercalcaemia, in which PTH is suppressed and other causes such as malignancy or vitamin D excess are pursued (PMID 36102025). That branching logic is why PTH is rarely interpreted without a simultaneous calcium result.

Sorting out low calcium

In hypocalcaemia, the question reverses. A review on the management of hypoparathyroidism characterised the disorder by hypocalcaemia with a PTH level that is low or inappropriately normal rather than appropriately elevated, and discussed conventional management with calcium and active vitamin D as well as PTH replacement approaches (PMID 36161671).

Monitoring kidney disease

PTH is also tracked serially in CKD. An older review of renal osteodystrophy described PTH as a central driver of the bone lesions seen in advanced kidney disease and discussed its role in classifying high-turnover versus low-turnover bone disease (PMID 12089954). A laboratory-perspective paper on haemodialysis patients examined how PTH is measured in that population specifically, covering preanalytical handling and method selection (PMID 31631422).

Other documented contexts

• Investigation of recurrent kidney stones or unexplained low bone density, where calcium and PTH are evaluated together as part of the mineral panel described in the clinical chemistry review (PMID 28939209).
• Follow-up after kidney transplantation, where tertiary hyperparathyroidism has been reported to persist (PMID 33956045).
• Differentiating inherited causes of hypercalcaemia, where a review of familial hypocalciuric hypercalcaemia described hypercalcaemia accompanied by normal or mildly elevated PTH together with low urinary calcium excretion (PMID 29083672).

What Published Studies Associate With High PTH Levels

"High PTH" is not a diagnosis in the literature; it is a finding whose meaning depends entirely on the accompanying calcium, phosphate, vitamin D and kidney function. Published reviews describe several distinct patterns.

Primary and normocalcaemic hyperparathyroidism

A review of normocalcaemic hyperparathyroidism described a phenotype in which PTH is persistently elevated while total and ionised calcium remain within the laboratory range, and researchers stressed that the label is only applied after secondary causes of PTH elevation — including vitamin D deficiency, reduced renal function, malabsorption and certain medications — have been excluded (PMID 30641527). The same review discussed uncertainty about how often this pattern progresses to classical hypercalcaemic disease (PMID 30641527).

Secondary hyperparathyroidism

When PTH rises as a physiological response to a stimulus such as low calcium, vitamin D insufficiency or declining renal function, the literature calls it secondary. The renal osteodystrophy review described progressive PTH elevation in advancing kidney disease and its skeletal consequences (PMID 12089954), and the CKD measurement review addressed how PTH results in this population are used and why fixed targets are difficult given assay differences (PMID 19812537).

Tertiary hyperparathyroidism

A review of tertiary hyperparathyroidism described the condition as autonomous, largely non-suppressible PTH secretion emerging after prolonged secondary stimulation, most often discussed in the context of long-standing kidney disease and after renal transplantation, and it reviewed medical and surgical management options reported in that setting (PMID 33956045).

Genetic mimics

The familial hypocalciuric hypercalcaemia review attributed the condition to inactivating variants affecting the calcium-sensing receptor pathway and reported that the resulting biochemistry — hypercalcaemia with non-suppressed PTH — can closely resemble primary hyperparathyroidism, with urinary calcium measurement described as a key discriminator (PMID 29083672).

What Published Studies Associate With Low PTH Levels

Low or inappropriately normal PTH in the presence of low calcium is the biochemical hallmark of hypoparathyroidism described in the management review, which covered post-surgical, autoimmune and genetic aetiologies and the conventional and hormone-replacement strategies reported for them (PMID 36161671). A 2024 study of patients with hypoparathyroidism examined corticosteroid rhythms in this population, illustrating that researchers have looked beyond calcium alone when characterising the condition (PMID 39167533).

Suppressed PTH with elevated calcium points the workup in a different direction. The hypercalcaemia review described this PTH-independent pattern as prompting evaluation for malignancy-associated hypercalcaemia, granulomatous disease, vitamin D excess and other non-parathyroid causes (PMID 36102025).

Assay and Interpretation Caveats: What Studies Report

Oxidation of the hormone

A review of PTH oxidation reported that methionine residues in the PTH molecule can be oxidised, that oxidised PTH shows reduced or absent biological activity, and that routine immunoassays do not distinguish oxidised from non-oxidised forms — meaning a measured concentration may include hormone that is not biologically active (PMID 32178977). The same review discussed assays developed to measure non-oxidised PTH and the ongoing debate about their clinical value (PMID 32178977).

Fragments and standardisation

The assay-problems review reported that circulating PTH fragments accumulate particularly when renal clearance is impaired and that this contributes to divergence between second- and third-generation methods, alongside the lack of a common calibrator (PMID 25916762). The CKD review similarly reported method-dependent differences that make numerical comparison across laboratories unreliable (PMID 19812537).

Preanalytical handling

The laboratory-perspective paper on haemodialysis patients addressed preanalytical variables in PTH determination — including specimen type, stability and the handling steps that precede analysis — and discussed how these affect reported values in that population (PMID 31631422). The broader clinical chemistry review likewise framed calcium and bone metabolism indices as sensitive to collection and processing conditions (PMID 28939209).

Biological variability

PTH is not a static analyte: it responds within minutes to changes in ionised calcium and shows diurnal variation, which is one reason the reviewed literature treats serial measurement and simultaneous calcium testing as standard practice rather than optional (PMID 28939209).

Why Interpretation Belongs to the Ordering Clinician

Every pattern above depends on context that a single number cannot supply: the concurrent calcium, the method used, kidney function, vitamin D status, medications and the clinical picture. Because assay results are method-dependent and not interchangeable across laboratories, as researchers reported in both the general assay review (PMID 25916762) and the CKD-focused review (PMID 19812537), a value read in isolation or compared against a range from a different platform can be misleading. This page does not interpret individual results and does not substitute for the clinician who ordered the test.

References

• Normocalcemic Hyperparathyroidism (Frontiers of Hormone Research, 2019)
• Tertiary hyperparathyroidism: a review (La Clinica Terapeutica, 2021)
• Management of Hypoparathyroidism (Journal of Bone and Mineral Research, 2022)
• Familial Hypocalciuric Hypercalcemia (2024)
• Oxidation of parathyroid hormone (Clinica Chimica Acta, 2020)
• PTH determination in hemodialyzed patients—A laboratory perspective (Seminars in Dialysis, 2019)
• Calcium and Bone Metabolism Indices (Advances in Clinical Chemistry, 2017)
• Corticosteroid rhythms in hypoparathyroid patients (European Journal of Endocrinology, 2024)
• [Renal osteodystrophy (II)] (Revista Medico-Chirurgicala, 2000)
• [Hypercalcemia — Diagnosis and Management] (Praxis, 2022)
• Parathyroid hormone measurement in CKD (Kidney International, 2010)
• Problems with the PTH assays (Annales d'Endocrinologie, 2015)